Xenon Pharmaceuticals Inc. company info

CIK 1582313
IRS Number 980661854
State of incorporation A1
Business address 200 - 3650 GILMORE WAY
None
BURNABY
A1
V5G 48W
Mail address 200 - 3650 GILMORE WAY
None
BURNABY
A1
V5G 48W

Short summary

Xenon Pharmaceuticals Inc. is a British Columbia, Canada company, with head office located at 200 - 3650 Gilmore Way Burnaby, British Columbia, Canada V5G 48W. In 2017 the company owned a total of 37.76 million USD worth of assets, including 36.66 million USD worth of current assets. 2014 was the year when the company amassed the most assets.

Xenon Pharmaceuticals Inc. Income Statement

Name [in Millions USD]2011201220132014201520162017Trends
Research and development 10.4612.3011.7715.1519.8325.57
Operating Expenses 17.4617.6417.2624.9426.6232.89
Operating Income (Loss) -3.159.7111.11-9.36-24.82-32.58
Interest expense 0.090.06
Income Tax Expense (Benefit) 000
Net income -4.3012.0313.02-15.75-23.00-30.70

Xenon Pharmaceuticals Inc. Balance Sheet

Name [in Millions USD]2011201220132014201520162017Trends
Cash and cash equivalents 13.9360.1635.0964.3535.2123.0917.20
Accounts Receivable, Net, Current 0.440.190.660.200.43
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment 14.1513.5414.5815.0815.64
Total assets 54.4976.5355.6954.2337.76
Current assets 49.8774.3553.3952.6336.66
Total current liabilities 18.2012.022.933.523.79
Long-term Debt, Excluding Current Maturities 5.48
Deferred Revenue, Noncurrent 11.890.16
Total liabilities 30.3712.183.033.779.26
Common Stock, Value, Issued 6.15147.82148.87173.84147.89
Retained Earnings (Accumulated Deficit) -116.75-111.80-128.97-157.58-177.14
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.51-0.99-0.99-0.99-0.99

Xenon Pharmaceuticals Inc. Cash Flow

Name [in Millions USD]2011201220132014201520162017Trends
Net income -4.3012.0313.02-15.75-23.00-30.70
Depreciation and amortization 0.790.710.741.040.860.65
Depreciation and amortization 0.790.710.74
Accounts receivable -11.230.08-0.210.11-0.120.23
Deferred revenue 35.49-16.36-14.41-11.62-0.16
Payments to Acquire Property, Plant, and Equipment 0.530.161.530.550.280.32
Net Cash Provided by (Used in) Investing Activities, Continuing Operations 0.49-11.47-3.2410.19-47.8424.29
Proceeds from Issuance of Common Stock 0.0542.640.2823.83
Cash and Cash Equivalents, Period Increase (Decrease) 46.23-22.2134.08-13.38-41.563.39